Barinthus Biotherapeutics (BRNS) Total Debt (2021)
Barinthus Biotherapeutics' (BRNS) quarterly Total Debt came in at $159000.0 in Q4 2021.
Barinthus Biotherapeutics (BRNS) Total Debt (2021) Analysis & Trends
Barinthus Biotherapeutics (BRNS) has 1 years of Total Debt data on file, last reported at $159000.0 in Q4 2021.
- Quarterly Total Debt changed N/A year-over-year to $159000.0 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $159000.0 (changed N/A YoY) and the FY2021 annual result came in at $159000.0, changed N/A from the prior year.
- Total Debt was little changed at $159000.0 in Q4 2021.
- In the past five years, Total Debt ranged from a high of $159000.0 in Q4 2021 to a low of $159000.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.79 Bn | 130.93 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 78.00 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.04 Bn | 50.91 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 42.05 Bn | 36.95 Bn | 1.53 Bn | 1.07 Bn |
| 6 | Alnylam Pharmaceuticals | 31.71 Bn | 28.40 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 27.66 Bn | 9.26 Bn | 668.28 Mn | 770.36 Mn |
| 8 | Insmed | 27.50 Bn | 26.33 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - | 9.34 Bn |
| 10 | Barinthus Biotherapeutics | 25.40 Mn | 25.40 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 159,000.00 |